Please login to the form below

Not currently logged in
Email:
Password:

Update on AZ-Merck deal

AZ will buy rights to several of Merck's marketed and pipeline products at a cost of $674m, as announced in an update regarding their joint venture

AstraZeneca (AZ) has announced that it will exercise one of its options under the provisions of the agreements relating to the restructuring of its joint venture with Merck in the US at a cost of $674m.

AZ will purchase rights to several Merck products, including the Crohn's Disease treatment Entocort, and blood pressure dugs Atacand, Lexxel and Plendil. Some pipeline drugs are also part of the deal, including the blood thinner Brilinta.

AZ and Merck have been partners on these and other drugs for years. The original sales-and-distribution deal dates to 1982, with a restructuring in 1998.

The deal also includes shares of the heartburn drugs Nexium and Prilosec, which AZ has the option to repurchase beginning in 2012.

By exercising this option under the agreement, a second option to repurchase Merck's interests in heartburn drugs Prilosec and Nexium in the US, is now exercisable by AZ in 2012, or in 2017, or if combined annual sales of the two products fall below a minimum amount.

2nd March 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics